Detalhe da pesquisa
1.
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 389(11): 1009-1022, 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646702
2.
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Cancer
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630908
3.
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Cancer
; 129(23): 3746-3760, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37622738
4.
Kinetics of response to first- and second-line therapies in multiple myeloma: Assessment by both M-spikes and light chains.
Eur J Haematol
; 108(3): 204-211, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34767270
5.
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Cancer
; 127(22): 4198-4212, 2021 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34314018
6.
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Future Oncol
; 17(16): 1987-2003, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33682447
7.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lancet Oncol
; 21(2): 207-221, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31859245
8.
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
Blood
; 131(8): 855-863, 2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29203585
9.
Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
Future Oncol
; 16(34): 2783-2798, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32875817
10.
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Lancet Oncol
; 19(12): 1641-1653, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442502
11.
Initial genome sequencing and analysis of multiple myeloma.
Nature
; 471(7339): 467-72, 2011 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-21430775
12.
Tyrosine phosphorylation of the Lyn Src homology 2 (SH2) domain modulates its binding affinity and specificity.
Mol Cell Proteomics
; 14(3): 695-706, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25587033
13.
Differential regulation of FGFR3 by PTPN1 and PTPN2.
Proteomics
; 15(2-3): 419-33, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25311528
14.
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
Br J Haematol
; 168(1): 46-54, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25146584
15.
Incorporating isatuximab in the treatment of multiple myeloma.
Lancet
; 394(10214): 2045-2047, 2019 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31735559
16.
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.
Blood
; 121(9): 1517-23, 2013 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23297129
17.
Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site.
J Oncol Pharm Pract
; 21(4): 285-92, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24781451
18.
Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution.
Br J Haematol
; 164(5): 722-8, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24266428
19.
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
Blood
; 120(14): 2817-25, 2012 Oct 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-22833546
20.
Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.
Am J Hematol
; 89(4): 363-8, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24273151